PR Newswire Clinical TrialsOriginal article
Laminar Pharma Announces "Last Patient, Last Visit" in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients
Phase 3LAM561Positive
AI Analysis
Summary
Laminar Pharma announced completion of the last patient visit in its Phase 2b/3 LAM561 trial for newly diagnosed glioblastoma patients. The trial milestone represents progress toward potential data readout and regulatory submission.
Clinical Trial Data
Phase
2b/3
Outcome Details
Last patient, last visit completed in Phase 2b/3 trial
Importance:6/10
Sentiment:
0.50
glioblastomamembrane lipid therapyclinical trial milestoneLPLV
Read the original article
Published by PR Newswire Clinical Trials on July 24, 2026 1:30 AM